Abstract: A phenol derivative of the formulaNU--A--X--R.sup.1wherein NU is a defined phenolic nucleus including a phenyl-hydroxynaphthyl; hydroxyphenyl-naphthyl; phenyl-hydroxyindanyl, phenyl-hydroxybenzothienyl or mono-hydroxyphenyl-ethylene or vinylene nucleus; wherein A is alkylene, alkenylene or alkynylene which may be interrupted by phenylene or other linkages, wherein R.sup.1 is hydrogen, or alkyl, alkenyl, alkynyl, cycloalkyl, halogenoalkyl, alkoxyalkyl, halogenoalkoxyalkyl, aryl or arylalkyl, or R.sup.1 is joined to R.sup.2, and wherein X is --CONR.sup.2 --, --CSNR.sup.2 --, --NR.sup.12 CO--, --NR.sup.12 CS--, --NR.sup.12 CONR.sup.2 --, ##STR1## --SO.sub.2 NR.sup.2 --or --CO--, or, when R.sup.1 is not hydrogen, is --NR.sup.12 COO--, --(PO)R.sup.2 13 , --S--, --SO--or --SO.sub.2 --, wherein R.sup.2 is hydrogen or alkyl, or R.sup.1 and R.sup.2 together form alkylene; wherein R.sup.12 is hydrogen or alkyl, and wherein R.sup.22 is hydrogen, cyano or nitro; or a salt thereof when appropriate.

Abstract: A steroid derivative of the formula:ST--A--X--R.sup.1wherein ST is a 7.alpha.-linked steroid nucleus of the general formula: ##STR1## wherein the double bond(s) between carbon atoms 6 and 7 and/or carbon atoms 8 and 9 are optional; wherein the aromatic ring A may optionally bear one or two halogen or alkyl substituents; wherein R.sup.3 is hydrogen, alkyl, or acyl; wherein R.sup.16 is hydrogen, alkyl or hydroxy; wherein either R.sup.17 is hydroxy or acyloxy and R.sup.27 is hydrogen, alkyl, alkenyl or alkynyl, or R.sup.17 and R.sup.27 together form oxo (.dbd.O); wherein R.sup.18 is alkyl; wherein A is alkylene, alkenylene or alkynylene optionally fluorinated and optionally interrupted by --O--, --S--, --SO--, --SO.sub.2 --, --CO--, --NR--, --NRCO--, --CONR--, --COO--, --OCO-- or phenylene, wherein R is hydrogen or alkyl; wherein R.sup.1 is hydrogen, alkyl, alkenyl, cycloalkyl, halogenoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl, arylalkyl, or dialkylaminoalkyl, or R.sup.1 is joined to R.sup.

Abstract: The disclosure relates to novel 17,18,19,20-tetranor-prostanoic acid derivatives having prostaglandin-type properties, to a method for their manufacture, and also to pharmaceutical or veterinary compositions containing said novel derivatives and a method of inducing luteolysis in an animal host by use of said novel derivatives.

Abstract: The disclosure relates to novel 4-cis-prostenoic acid derivatives, for example 16-(3-chlorophenoxy)-9.alpha.,11.alpha.,15-trihydroxy-17,18,19,20-tetranor -4-cis, 13-trans-prostadienoic acid, to chemical processes for their manufacture, to pharmaceutical and veterinary compositions containing them, and to the use of the compounds in a method of luteolysis, a method of inhibiting blood platelet aggregation, and a method of inhibiting gastric acid production.

Abstract: The disclosure relates to novel 4-cis-prostenoic acid derivatives, for example 16-(3-chlorophenoxy)-9.alpha.,11.alpha.,15-trihydroxy-17,18,19,20-tetranor -4-cis, 13-trans-prostadienoic acid, to chemical processes for their manufacture, to pharmaceutical and veterinary compositions containing them, and to the use of the compounds in a method of luteolysis, a method of inhibiting blood platelet aggregation, and a method of inhibiting gastric acid production.

Abstract: The disclosure relates to .omega.-aryl substituted .omega.-nor prostaglandin analogues bearing an oxygenated function at C-10, such as a hydroxy radical, or a 9,10- or 10,11-epoxide. A typical compound is 16-(3-chlorophenoxy)-9.alpha.,10.beta.,11.alpha.,15.alpha.-tetrahydroxy-17 ,18,19,20-tetranor-5-cis,13-trans-prostadienoic acid. Also disclosed are chemical processes for the manufacture of said compounds, pharmaceutical and veterinary compositions containing said compounds, and a method of achieving luteolysis in mammals by the use of such compounds.

Abstract: The disclosure relates to .omega.-aryl substituted .omega.-nor prostaglandin analogues bearing an oxygenated function at C-10, such as a hydroxy radical, or a 9,10- or 10,11-epoxide. A typical compound is 16-(3-chlorophenoxy)-9.alpha.,10.beta.,11.alpha.,15.alpha.-tetrahydroxy-17 ,18,19,20-tetranor-5-cis,13-trans-prostadienoic acid. Also disclosed are chemical processes for the manufacture of said compounds, pharmaceutical and veterinary compositions containing said compounds, and a method of achieving luteolysis in mammals by the use of such compounds.

Abstract: The disclosure relates to novel pentanor prostaglandin analogues, for example 15-(5-chloroindan-2-yl)-9.alpha.,11.alpha.,15-trihydroxy-16,17,18,19,20-pe ntanor-5-cis,13-trans-prostadienoic acid and 15-(5-chloroindan-2-yl)-11.alpha.,15-dihydroxy-9-oxo-16,17,18,19,20-pentan or-5-cis,13-trans-prostadienoic acid and the 1-ester and 1-alcohol derivatives thereof, to a process for their manufacture, to compositions containing them, and to their use in a method of inducing luteolysis.

Abstract: This invention relates to novel 15-, 16- and 17-heterocyclyl nor-prostanoic acid derivatives, for example 9.alpha.,11.alpha.,15-trihydroxy-16-(indol-5-yloxy)-17,18,19,20-tetranor-5 -cis, 13-trans-prostadienoic acid, which have a unique profile of Prostaglandin-like properties, and to processes for their manufacture, and also to pharmaceutical or veterinary compositions containing one of said novel derivatives, and a method of inducing luteolysis in an animal host by administering one of said novel derivatives.

Abstract: The disclosure relates to novel ethers and glycosides of prostaglandin analogues, for example 16-(3-chlorophenoxy)-1-methoxy-17,18,19,20-tetranor-5-cis,13-trans-prostad ien-9.alpha. ,11.alpha. ,15.alpha.-triol, to a process for their manufacture, to compositions containing them, and to their use in a method of inducing luteolysis in a warm-blooded animal host.

Abstract: The disclosure relates to novel pentanor prostaglandin analogues, for example 15-(5-chloroindan-2-yl)-9.alpha.,11.alpha.,15-trihydroxy-16,17,18,19,20-pe ntanor-5-cis, 13-trans-prostadienoic acid and 15-(5-chloroindan-2-yl)-11.alpha.,15-dihydroxy-9-oxo-16,17,18,19,20-pentan or-5-cis,13-trans-prostadienoic acid and the 1-ester and 1-alcohol derivatives thereof, to a process for their manufacture, to compositions containing them, and to their use in a method of inducing luteolysis.

Abstract: Prostanoic acid derivatives having luteolytic activity are provided. A representative compound is 16-(6-chloropyrid-2-yloxy)-9.alpha., 11.alpha., 15-trihydroxy-17, 18, 19, 20-tetranor-5-cis, 13-trans-prostadienoic acid.